Monitoring immunosuppression with measures of NFAT decreases cancer incidence

Clinical Immunology

Volumn 132, Issue 3, 2009, Pages 305-311

  Giese, Thomas ^a   Sommerer, Claudia ^a   Zeier, Martin ^a   Meuer, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; ; Immunomonitoring; Immunosuppression; ; Transplantation;

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; STEROID; TRANSCRIPTION FACTOR NFAT;

AGED; ANAMNESIS; BASAL CELL CARCINOMA; CANCER INCIDENCE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; LOW DRUG DOSE; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SHORT SURVEY; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

AGED; CYCLOSPORINE; CYTOKINES; DRUG MONITORING; GENE EXPRESSION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MONITORING, IMMUNOLOGIC; NFATC TRANSCRIPTION FACTORS; SKIN NEOPLASMS;

EID: 67651160356     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.520     Document Type: Short Survey

References (56)

1. Giese T., Zeier M., Schemmer P., Uhl W., Schoels M., Dengler T., Buechler M., and Meuer S. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 77 3 (2004) 339-344
2. Giese T., Zeier M., and Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol. Dial Transplant. 19 Suppl 4 (2004) IV55-IV60
3. Hariharan S., Johnson C.P., Bresnahan B.A., Taranto S.E., McIntosh M.J., and Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342 9 (2000) 605-612
4. Wong G., and Chapman J.R. Cancers after renal transplantation. Transplant. Rev. (Orlando) 22 2 (2008) 141-149
5. 2007 OPTN/SRTR Annual Report 1997-2006. HHS/HRSA/HSB/DOT.
6. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 4 3 (2004) 378-383
7. Howard R.J., Patton P.R., Reed A.I., Hemming A.W., Van der Werf W.J., Pfaff W.W., Srinivas T.R., and Scornik J.C. The changing causes of graft loss and death after kidney transplantation. Transplantation 73 12 (2002) 1923-1928
8. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 Suppl. 2 (2005) S254-S264
9. Dantal J., and Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol. Dial Transplant. 22 Suppl. 1 (2007) i4-i10
10. Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., and Zeier M. Malignancy in renal transplantation. J. Am. Soc. Nephrol. 15 6 (2004) 1582-1588
11. Lutz J., and Heemann U. Tumours after kidney transplantation. Curr. Opin. Urol. 13 2 (2003) 105-109
12. Buell J.F., Hanaway M.J., Trofe J., Gross T.G., Beebe T.M., Alloway R.R., First M.R., and Woodle E.S. De novo breast cancer in renal transplant recipients. Transplant. Proc. 34 5 (2002) 1778-1779
13. Buell J.F., Papaconstantinou H.T., Skalow B., Hanaway M.J., Alloway R.R., and Woodle E.S. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant. Proc. 37 2 (2005) 960-961
14. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dreno B., and Soulillou J.P. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351 9103 (1998) 623-628
15. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., and Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 6719 (1999) 530-534
16. Basu A., Contreras A.G., Datta D., Flynn E., Zeng L., Cohen H.T., Briscoe D.M., and Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 68 14 (2008) 5689-5698
17. Opelz G., Naujokat C., Daniel V., Terness P., and Dohler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81 9 (2006) 1227-1233
18. Koehl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 9 (2004) 1319-1326
19. Gutierrez-Dalmau A., and Campistol J.M. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol. Dial. Transplant. 22 Suppl. 1 (2007) i11-i16
20. Campistol J.M., Albanell J., Arns W., et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol. Dial Transplant. 22 Suppl. 1 (2007) i36-i41
21. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352 13 (2005) 1317-1323
22. Di Paolo S., Teutonico A., Leogrande D., Capobianco C., and Schena P.F. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?. J. Am. Soc. Nephrol. 17 8 (2006) 2236-2244
23. Frost P., Shi Y., Hoang B., and Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26 16 (2007) 2255-2262
24. Di Paolo S., Teutonico A., Ranieri E., Gesualdo L., and Schena P.F. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am. J. Kidney Dis. 49 3 (2007) 462-470
25. Goudar R.K., Shi Q., Hjelmeland M.D., et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. 4 1 (2005) 101-112
26. Frost P., Moatamed F., Hoang B., Shi Y., Gera J., Yan H., Gibbons J., and Lichtenstein A. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104 13 (2004) 4181-4187
27. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 7 (2005) 883-889
28. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 17 2 (2006) 581-589
29. Pascual J. Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol. Dial Transplant. 22 Suppl. 1 (2007) i27-i35
30. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357 25 (2007) 2562-2575
31. Wilson R.E., Hager E.B., Hampers C.L., Corson J.M., Merrill J.P., and Murray J.E. Immunologic rejection of human cancer transplanted with a renal allograft. N. Engl. J. Med. 278 9 (1968) 479-483
32. Matter B., Zukoski C.F., Killen D.A., and Ginn E. Transplanted carcinoma in an immunosuppressed patient. Transplantation 9 1 (1970) 71-74
33. Morath C., Rohmeiss P., Schwenger V., et al. Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft. Transplantation 80 4 (2005) 540-542
34. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 8377 (1984) 583-587
35. Wijnveen A.C., Persson H., Bjorck S., and Blohme I. Disseminated Kaposi's sarcoma-full regression after withdrawal of immunosuppressive therapy: report of a case. Transplant. Proc. 19 5 (1987) 3735-3736
36. Duman S., Toz H., Asci G., et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol. Dial Transplant. 17 5 (2002) 892-896
37. Friedlaender M.M., Rubinger D., Rosenbaum E., Amir G., and Siguencia E. Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 73 11 (2002) 1849-1850
38. Otley C.C., Coldiron B.M., Stasko T., and Goldman G.D. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch. Dermatol. 137 4 (2001) 459-463
39. Chuang F.R., Hsieh H., Hsu K.T., and Huang H.F. Increasing transplant cancer patient survival by conversion of immunosuppressive agents. Transplant. Proc. 28 3 (1996) 1346-1347
40. Kahan B.D. Cyclosporine. N. Engl. J. Med. 321 25 (1989) 1725-1738
41. Kahan B.D., Welsh M., Schoenberg L., Rutzky L.P., Katz S.M., Urbauer D.L., and Van Buren C.T. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62 5 (1996) 599-606
42. Morris R.G., Russ G.R., Cervelli M.J., Juneja R., McDonald S.P., and Mathew T.H. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther. Drug Monit. 24 4 (2002) 479-486
43. Oellerich M., and Armstrong V.W. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?. Ther. Drug Monit. 24 1 (2002) 40-46
44. Thervet E., Pfeffer P., Scolari M.P., et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 76 6 (2003) 903-908
45. Midtvedt K., Fauchald P., Bergan S., et al. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?. Transplantation 76 8 (2003) 1236-1238
46. Einecke G., Mai I., Fritsche L., Slowinski T., Waiser J., Neumayer H.H., and Budde K. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol. Dial. Transplant. 19 1 (2004) 215-222
47. Sommerer C., Konstandin M., Dengler T., Schmidt J., Meuer S., Zeier M., and Giese T. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 82 10 (2006) 1280-1285
48. Stein C.M., Murray J.J., and Wood A.J. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin. Chem. 45 9 (1999) 1477-1484
49. Hartel C., Fricke L., Schumacher N., Kirchner H., and Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 48 12 (2002) 2225-2231
50. Halloran P.F., Helms L.M., Kung L., and Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68 9 (1999) 1356-1361
51. van Rossum H.H., Romijn F.P., Sellar K.J., Smit N.P., van der Boog P.J., de Fijter J.W., and van Pelt J. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin. Chem. 54 3 (2008) 517-524
52. Sottong P.R., Rosebrock J.A., Britz J.A., and Kramer T.R. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin. Diagn. Lab. Immunol. 7 2 (2000) 307-311
53. Wimmer C.D., Rentsch M., Crispin A., Illner W.D., Arbogast H., Graeb C., Jauch K.W., and Guba M. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 71 12 (2007) 1271-1278
54. Sommerer C., Hartschuh W., Enk A., Meuer S., Zeier M., and Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin. Transplant. 22 5 (2008) 549-554
55. Sommerer C., Giese T., Schmidt J., Meuer S., and Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 85 1 (2008) 15-21
56. http://www.ctstransplant.org/.